More and Better Lungs: Ex-Vivo Perfusion of Lungs from Non-Heart-Beating Donors
更多更好的肺:来自无心跳供体的肺的离体灌注
基本信息
- 批准号:8713424
- 负责人:
- 金额:$ 167.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-01 至 2016-09-30
- 项目状态:已结题
- 来源:
- 关键词:Accident and Emergency departmentAddressAmericasAncillary StudyAnimal ModelAreaBiological AssayBiological MarkersBlood CirculationBlood donorBlood flowBrain DeathBrain InjuriesCategoriesCause of DeathCessation of lifeClinical TrialsCountyEmergency medical serviceFunctional disorderFutureGoalsGovernment AgenciesHealthHealthcare SystemsHeartHourHumanHuman ResourcesIncubatedIndividualInstitutional Review BoardsLaw EnforcementLeadershipLiquid substanceLungLung TransplantationLung diseasesMedical ExaminersMethodsMetricNatural ImmunityNorth CarolinaOrganOrgan DonorOrgan ProcurementsOrgan RetrievalsOrgan TransplantationOutcomePatient CarePatientsPerfusionPhase II Clinical TrialsPoliciesPopulationProceduresProtocols documentationQuality of lifeReaction TimeReperfusion InjuryRetrievalSafetySample SizeScanningSerologicalServicesSourceStagingState GovernmentStructure of parenchyma of lungSudden DeathTechnologyTestingTimeTransplantationTransportationUnited StatesUp-RegulationVentilatorX-Ray Computed Tomographycompare effectivenessex vivo perfusionimprovedinjuredmetabolomicsmortalityphase 2 studyphase 3 studysuccess
项目摘要
DESCRIPTION (provided by applicant): Lung disease is the third leading cause of death in the United States. Lung transplant could improve quality of life and enhance survival in many lung disease patients. However, lung transplantation is severely limited by an inadequate number of suitable lungs for transplant from conventional organ donors - individuals who sustain a lethal brain injury, but who are incubated and ventilated before brain death occurs. Because most lungs from conventional organ donors are not suitable for transplant, only 1,700 lung transplants are performed annually in the U.S. However, lung tissue remains viable after circulatory arrest. In animal models, the PI of this project showed that lungs can function well after transplant, even if retrieved hours after death. Each year, more than 750,000 people in the U.S. are victims of sudden death; if lungs could be retrieved for transplant from some of these people - non-heart-beating donors (NHBDs) - the lung donor shortage could be eliminated. The PI has performed ex-vivo lung perfusion (EVLP) to determine suitability of human lungs initially turned down for transplant from conventional organ donors. Safety of transplanting these lungs after EVLP has recently been demonstrated. This proposed Phase 2 clinical trial will demonstrate safety and efficacy of transplant of lungs retrieved from NHBDs after death, assessed by EVLP, We will accomplish this Specific Aim: To demonstrate non-inferiority of lung transplant using lungs retrieved from NHBDs assessed by EVLP compared to lung transplant from conventional brain dead organ donors. We will obtain lungs from Maastricht Category 1 and 2 NHBDs in a large-population North Carolina county (Wake) and from targeted emergency rooms. We will apply established methods of EVLP and ex-vivo CT scan to evaluate suitability for transplant. Acceptable lungs will be transplanted at UNC and Duke under IRB-approved protocols. Outcomes will be compared to patients contemporaneously transplanted with lungs from conventional organ donors.
Because lungs from NHBDs have not been injured by a prolonged interval of brain death, lungs retrieved from NHBDs may not only be much more plentiful; they may be superior to lungs currently being transplanted from conventional brain-dead donors. Timely retrieval of lungs from NHBDs requires coordination of EMS, law enforcement, medical examiners, and OPO personnel. Through the Office of the N.C. Secretary of Health and Human Services, we commenced a dialogue with leadership of state agencies to facilitate timely lung retrieval from NHBDs. We will use experts at Lung Banks of America, a not-for-profit corporation, to analyze time flow metrics from declaration of death to lung retrieval. With N.C. state government agencies, we will develop practices and policies to improve the yield of successful lung retrieval from NHBDs that can be implemented in N.C. and across the U.S. An ancillary project will determine metabolomic biomarkers for suitability of NHBD lungs for EVLP assessment, and biomarkers associated with poor function after lung transplant. Successful study completion will revolutionize lung transplant and the care of patients with end-stage lung disease.
描述(申请人提供):肺部疾病是美国第三大死因。肺移植可以改善许多肺部疾病患者的生活质量,提高患者的存活率。然而,肺移植受到传统器官捐赠者合适肺移植数量不足的严重限制-这些捐赠者遭受致命的脑损伤,但在脑死亡发生之前进行孵化和通风。由于大多数来自传统器官捐赠者的肺不适合移植,美国每年只进行1700例肺移植。然而,在循环停止后,肺组织仍然活着。在动物模型中,该项目的PI表明,肺在移植后可以正常工作,即使在死亡后几个小时被取回。在美国,每年有超过75万人是猝死的受害者;如果能从其中一些人--非心脏跳动捐赠者(NHBD)--那里取出肺进行移植,那么肺捐赠者的短缺就可以消除。PI进行了体外肺灌流(EVLP),以确定最初拒绝接受传统器官捐赠者移植的人肺的适宜性。EVLP后移植这些肺的安全性最近已被证明。这项拟议的第二阶段临床试验将证明通过EVLP评估死后从NHBD取回的肺移植的安全性和有效性。我们将实现这一特定目标:证明使用EVLP评估的NHBD取回的肺移植与传统脑死亡器官捐赠者的肺移植相比并不逊色。我们将从人口众多的北卡罗来纳州韦克县(Wake)的马斯特里赫特1类和2类NHBD以及目标急诊室获得肺。我们将应用已建立的EVLP和体外CT扫描方法来评估移植的适宜性。可接受的肺将根据IRB批准的方案在北卡罗来纳大学和杜克大学进行移植。结果将与同期接受传统器官捐赠者肺移植的患者进行比较。
由于NHBD的肺没有因长时间的脑死亡而受损,从NHBD中提取的肺可能不仅要丰富得多,而且可能比目前从传统脑死亡捐赠者身上移植的肺更好。及时从NHBD中取出肺部需要EMS、执法、法医和OPO人员的协调。通过北卡罗来纳州卫生与公众服务部部长办公室,我们开始与州机构的领导层进行对话,以促进及时从NHBDS中取出肺部。我们将使用非营利性公司美国肺脏银行的专家来分析从宣布死亡到取回肺部的时间流指标。我们将与北卡罗来纳州政府机构一起制定实践和政策,以提高从NHBD中成功取出肺的产量,这些做法和政策可以在北卡罗来纳州和全美实施。一个辅助项目将确定NHBD肺是否适合进行EVLP评估的代谢组生物标记物,以及与肺移植后功能不良相关的生物标记物。研究的成功完成将给肺移植和终末期肺部疾病患者的护理带来革命性的变化。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Assessment of Lungs for Transplant Recovered from Uncontrolled Donation after Circulatory Determination of Death Donors.
死亡捐献者循环测定后对不受控制的捐献恢复的肺进行评估。
- DOI:10.1513/annalsats.201609-687mg
- 发表时间:2017
- 期刊:
- 影响因子:8.3
- 作者:Egan,Thomas;Blackwell,John;Birchard,Katherine;Haithcock,Benjamin;Long,Jason;Gazda,Stephen;Casey,Nissa;Thys,Caitlin
- 通讯作者:Thys,Caitlin
Lung Transplant From an Uncontrolled Donation After Circulatory Determination of Death Donor: Moving to Other Countries.
循环确定死亡捐献者后不受控制的捐献进行肺移植:转移到其他国家。
- DOI:10.1111/ajt.13658
- 发表时间:2016
- 期刊:
- 影响因子:0
- 作者:Egan,TM
- 通讯作者:Egan,TM
Overcoming challenges of lung recovery from uDCDDs - Felicidades!
克服 uDCDD 肺部恢复的挑战 - 祝你好运!
- DOI:10.1111/ajt.15506
- 发表时间:2019
- 期刊:
- 影响因子:0
- 作者:Egan,ThomasM;Requard3rd,JohnJacob
- 通讯作者:Requard3rd,JohnJacob
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas M. Egan其他文献
Improved results of lung transplantation for patients with cystic fibrosis.
囊性纤维化患者的肺移植效果得到改善。
- DOI:
- 发表时间:
1995 - 期刊:
- 影响因子:6
- 作者:
Thomas M. Egan;Frank C. Detterbeck;M. Mill;L. Paradowski;Rudy P. Lackner;W David Ogden;James R. Yankaskas;Jan H. Westerman;Jeanette T. Thompson;Meredith A. Weiner;E. Cairns;Benson R. Wilcox - 通讯作者:
Benson R. Wilcox
Predictors of death on the UNOS lung transplant waiting list: results of a multivariate analysis.
UNOS 肺移植等候名单上死亡的预测因素:多变量分析的结果。
- DOI:
10.1016/s1053-2498(02)00921-x - 发表时间:
2001 - 期刊:
- 影响因子:0
- 作者:
Thomas M. Egan;Keith P. McCullough;Susan Murray;R. Bastami;R. Merion;Edward R. Garrity;F. L. Grover;W. Ring;Robert C. Robbins;E. Trulock;D. Wood;Lonnie Edwards - 通讯作者:
Lonnie Edwards
Analysis of cystic fibrosis referrals for lung transplantation.
囊性纤维化转诊肺移植的分析。
- DOI:
10.1378/chest.107.5.1323 - 发表时间:
1995 - 期刊:
- 影响因子:9.6
- 作者:
Paola Ciriaco;Thomas M. Egan;E. Cairns;Jeanette T. Thompson;Frank C. Detterbeck;L. Paradowski - 通讯作者:
L. Paradowski
Gene Expression Profile of Ischemia-reperfusion Injury in Human Lung Transplantatio
- DOI:
10.1378/chest.124.4_meetingabstracts.99s-b - 发表时间:
2003-01-01 - 期刊:
- 影响因子:
- 作者:
Eric Olson;Jianping Jin;William Funkhouser;Yuechuan Yuan;Scott Randell;Thomas M. Egan - 通讯作者:
Thomas M. Egan
When does the lung die? Kfc, cell viability, and adenine nucleotide changes in the circulation-arrested rat lung.
肺什么时候死亡?
- DOI:
10.1152/jappl.1997.83.1.247 - 发表时间:
1997 - 期刊:
- 影响因子:3.3
- 作者:
Thomas M. Egan;Randy M. Becker;J. Lemasters;Ya;Kuo Chu Hwang;Cheng;Yih;Susan S. Smyth;William K. Funkhouser;Keith Burridge;S. H. Randell;Monica Casiraghi;J. Abano;Jason R. Tatreau;M. Sevala - 通讯作者:
M. Sevala
Thomas M. Egan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas M. Egan', 18)}}的其他基金
Novel Ultrasonic Methods for the Assessment of Pulmonary Edema
评估肺水肿的超声新方法
- 批准号:
10246307 - 财政年份:2020
- 资助金额:
$ 167.6万 - 项目类别:
More and Better Lungs: Ex-Vivo Perfusion of Lungs from Non-Heart-Beating Donors
更多更好的肺:来自无心跳供体的肺的离体灌注
- 批准号:
8427986 - 财政年份:2013
- 资助金额:
$ 167.6万 - 项目类别:
CTRIP Ex-vivo perfusion and ventilation of lungs to assess transplant suitability
CTRIP 肺离体灌注和通气以评估移植适宜性
- 批准号:
7939804 - 财政年份:2009
- 资助金额:
$ 167.6万 - 项目类别:
CTRIP Ex-vivo perfusion and ventilation of lungs to assess transplant suitability
CTRIP 肺离体灌注和通气以评估移植适宜性
- 批准号:
7853226 - 财政年份:2009
- 资助金额:
$ 167.6万 - 项目类别:
ISCHEMIC INJURY IN CADAVER DONORS FOR LUNG TRANSPLANT
肺移植尸体捐献者的缺血性损伤
- 批准号:
6527620 - 财政年份:2001
- 资助金额:
$ 167.6万 - 项目类别:
ISCHEMIC INJURY IN CADAVER DONORS FOR LUNG TRANSPLANT
肺移植尸体捐献者的缺血性损伤
- 批准号:
6661139 - 财政年份:2001
- 资助金额:
$ 167.6万 - 项目类别:
ISCHEMIC INJURY IN CADAVER DONORS FOR LUNG TRANSPLANT
肺移植尸体捐献者的缺血性损伤
- 批准号:
6617944 - 财政年份:2001
- 资助金额:
$ 167.6万 - 项目类别:
ISCHEMIC INJURY IN CADAVER DONORS FOR LUNG TRANSPLANT
肺移植尸体捐献者的缺血性损伤
- 批准号:
6332174 - 财政年份:2001
- 资助金额:
$ 167.6万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 167.6万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 167.6万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 167.6万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 167.6万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 167.6万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 167.6万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 167.6万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 167.6万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 167.6万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 167.6万 - 项目类别:
Research Grant














{{item.name}}会员




